vs
Side-by-side financial comparison of Context Therapeutics Inc. (CNTX) and CXApp Inc. (CXAI). Click either name above to swap in a different company.
Context Therapeutics Inc. is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× CXApp Inc.). CXApp Inc. runs the higher net margin — -544.1% vs -1403.9%, a 859.8% gap on every dollar of revenue. On growth, Context Therapeutics Inc. posted the faster year-over-year revenue change (328.2% vs -38.5%). Context Therapeutics Inc. produced more free cash flow last quarter ($-1.9M vs $-3.6M). Over the past eight quarters, Context Therapeutics Inc.'s revenue compounded faster (154.3% CAGR vs -25.0%).
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
CNTX vs CXAI — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.0M |
| Net Profit | $-17.5M | $-5.6M |
| Gross Margin | — | 86.9% |
| Operating Margin | -1503.7% | -576.9% |
| Net Margin | -1403.9% | -544.1% |
| Revenue YoY | 328.2% | -38.5% |
| Net Profit YoY | -197.2% | -56.7% |
| EPS (diluted) | $-0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | $1.2M | $1.9M | ||
| Q2 24 | $840.1K | $1.8M | ||
| Q1 24 | — | $1.8M |
| Q4 25 | — | $-5.6M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | — | $-3.1M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | $-17.5M | $-5.4M | ||
| Q2 24 | $-2.3M | $-5.3M | ||
| Q1 24 | — | $-5.2M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 89.0% | ||
| Q2 25 | — | 86.0% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 86.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 80.0% | ||
| Q1 24 | — | 82.0% |
| Q4 25 | — | -576.9% | ||
| Q3 25 | — | -343.4% | ||
| Q2 25 | — | -336.1% | ||
| Q1 25 | — | -306.0% | ||
| Q4 24 | — | -169.7% | ||
| Q3 24 | -1503.7% | -194.3% | ||
| Q2 24 | -367.6% | -206.7% | ||
| Q1 24 | — | -197.3% |
| Q4 25 | — | -544.1% | ||
| Q3 25 | — | -283.4% | ||
| Q2 25 | — | -256.7% | ||
| Q1 25 | — | -132.0% | ||
| Q4 24 | — | -213.6% | ||
| Q3 24 | -1403.9% | -286.5% | ||
| Q2 24 | -268.3% | -297.6% | ||
| Q1 24 | — | -284.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.04 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $11.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $83.9M | $14.0M |
| Total Assets | $86.3M | $32.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $4.9M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | — | $4.9M | ||
| Q3 24 | $84.8M | — | ||
| Q2 24 | $101.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $14.0M | ||
| Q3 25 | — | $15.2M | ||
| Q2 25 | — | $14.3M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $83.9M | $13.6M | ||
| Q2 24 | $101.1M | $16.3M | ||
| Q1 24 | — | $20.9M |
| Q4 25 | — | $32.4M | ||
| Q3 25 | — | $28.5M | ||
| Q2 25 | — | $29.6M | ||
| Q1 25 | — | $29.3M | ||
| Q4 24 | — | $31.8M | ||
| Q3 24 | $86.3M | — | ||
| Q2 24 | $102.7M | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.9M | $-3.6M |
| Free Cash FlowOCF − Capex | $-1.9M | $-3.6M |
| FCF MarginFCF / Revenue | -156.0% | -355.5% |
| Capex IntensityCapex / Revenue | 0.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-10.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | $-979.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-1.9M | $-2.1M | ||
| Q2 24 | $-3.4M | $-1.9M | ||
| Q1 24 | — | $-650.0K |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | $-984.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.9M | $-2.1M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-668.0K |
| Q4 25 | — | -355.5% | ||
| Q3 25 | — | -248.1% | ||
| Q2 25 | — | -247.2% | ||
| Q1 25 | — | -80.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -156.0% | -109.3% | ||
| Q2 24 | — | -108.6% | ||
| Q1 24 | — | -36.7% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.6% | 0.2% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
